The fusion of 5' parts of the BCR gene to the ABL gene at the second exon yields several forms of an oncogenic Bcr-Abl oncoprotein observed in several types of Philadelphia chromosome positive leukemia patients. The first exon of the BCR gene is a critical part of this fusion, as the coiled-coil domain at the amino terminal domain of the Bcr protein causes oligomerization of the Bcr-Abl oncoprotein forming tetramers, thereby activating the tyrosine kinase activity of the normally silent c-Abl protein. Another consequence of this Bcr-Abl fusion is the extensive autophosphorylation of the cis Bcr protein sequences on tyrosine residues. This review will summarize the effects of Bcr-Abl autophosphorylation on tyrosines as they relate to the oncogenic activity of Bcr-Abl, and as a means to inactivate the serine/threonine kinase activity of the Bcr protein. The review also discusses our findings that show that phosphoserine Bcr by means of a unique structure, binds to the Abl SH2 domain of the Bcr-Abl oncoprotein, and as a result this SH2 binding inhibits the oncogenic effects of the oncoprotein. Our results indicate that one effect of this binding is inhibition of the Bcr-Abl tyrosine kinase. Serine 354 of Bcr plays a major role in this inhibition. In the case of Bcr(64-413), serine 354 is required for the formation of the unique Bcr structure that binds to the Abl SH2 domain.
Introduction
More than 10 years ago my laboratory began studies on the role of the BCR gene and the Bcr protein in chronic myelogenous leukemia (CML) caused by the Bcr-Abl oncoprotein. Initially, the Bcr protein was characterized by generating a number of anti-peptide Bcr antibodies. These antibodies proved to be very useful for isolating and characterizing the Bcr-Abl oncoprotein and the normal Bcr protein. The first application of these antibodies allowed us to detect the P210 Bcr-Abl protein in CML patient cell line (W Kloetzer and R Arlinghaus, Cold Spring Harbor RNA tumor Virus meeting, 1984; Kloetzer et al., 1985) . This was about the same time that the Witte group demonstrated that Bcr-Abl has an activated tyrosine kinase activity (Konopka et al., 1984) . These antibodies were also useful in sorting out the structure of the P190 BCR-ABL tyrosine kinase (Kurzrock et al., 1987) . The Bcr antibodies were also useful in detecting the serine/ threonine kinase encoded by the Bcr protein (Li et al., 1989) . It was observed that the Bcr sequence contains a similar pattern of protein sequences found in all serine/ threonine kinases, yet Bcr had significant changes in its sequence, suggesting that Bcr was a novel kinase (Li et al., 1989) . Subsequent studies by Maru and Witte provided convincing evidence that Bcr is indeed a novel serine/threonine kinase, and that the kinase domain has elements that resemble kinases like pyruvate kinase . The role of the Bcr serine/ threonine kinase in the oncogenic effects of the Bcr-Abl protein was further investigated in our laboratory. First, the Bcr protein itself was shown to be a target for tyrosine phosphorylation by Bcr-Abl . However, these studies revealed that only a minor fraction of total Bcr was tyrosine-phosphorylated in a CML cell line. In addition, a minor fraction of Bcr was tightly associated with P210 BCR-ABL (Campbell et al., 1990) , most likely by way of cooligomerization with Bcr-Abl (McWhirter and Wang, 1997) .
Bcr-Abl autophosphorylates at sites encoded by the first exon of BCR
The fusion of Bcr sequences activates the Abl tyrosine kinase causing autophosphorylation of the Bcr-Abl oncoprotein on tyrosine residues. Surprisingly, the predominant sites of tyrosine phosphorylation are located within Bcr protein sequences encoded by the first exon . This was initially determined by comparing phosphotryptic peptide maps of c-Abl, P210 BCR-ABL and P185 BCR-ABL. Most of the phosphotryptic peptides resulting from the in vitro Bcr-Abl kinase assay are shared between the P210 and P185 forms of Bcr-Abl oncoprotein. The c-Abl specific peptides are minor components of the Bcr-Abl autokinase reaction products. Since P185 BCR-ABL contains only Bcr sequences encoded by the first exon of BCR but not other BCR exons, it was concluded that the major sites of Bcr-Abl autophosphorylation were present in sequences encoded by the first exon of BCR .
Peptide mapping studies of site-directed mutants of Bcr-Abl when compared to wild-type Bcr-Abl suggested that tyrosine residues (Y) 177, Y283, Y328 and Y360 are sites of tyrosine phosphorylation resulting from Bcr-Abl autophosphorylation (Pendergast et al., 1993; Puil et al., 1994; Liu et al., 1996b; Wu et al., 1998) . In agreement with our earlier findings , all of these sites are located within the first exon coding sequence of the BCR gene. Y177 (Pendergast et al., 1993) and Y360 (Liu et al., 1996b) were also identified as sites of phosphorylation in P210 BCR-ABL expressed within cells.
Phosphotyrosine sequence-specific antibodies were also developed against pTyr 328 and pTyr 360 of Bcr to determine whether these sites were phosphorylated within cellular Bcr-Abl proteins and Bcr proteins. The Bcr protein co-expressed with BcrAbl is phosphorylated at these sites just as in the cis Bcr sequences within the Bcr-Abl oncoprotein, itself Liu et al., 1996b; Wu et al., 1998) . Besides pTyr sites mentioned above, additional sites of Bcr tyrosine phosphorylation undoubtedly exist but have not yet been identified. The known functional consequences of the sites of Bcr tyrosine phosphorylation are described below.
Activation of the Ras pathway
The role of Y177 phosphorylation was identified in a series of experiments published by Pendergast et al. (1993) , and confirmed by Puil et al. (1994) . Briefly, the wild-type Bcr-Abl oncoprotein binds tightly to the Grb2 adaptor protein through one of Grb2 protein's two SH2 domains; Grb2 in turn binds to the GDP exchange protein Sos, and it in turn binds to Ras. However, the Y177F Bcr-Abl mutant protein is much less effective in binding the Grb2 protein. Moreover, the Y177F mutant fails to generate the persistent levels of Ras/GTP observed in cells expressing the wild-type Bcr-Abl protein. Also, Bcr-Abl activates a down-stream effector of the Ras pathway, whereas the Y177F mutant is deficient in generating the signal produced by the activated Ras pathway (Pendergast et al., 1993) . Puil et al. (1994) confirmed that Bcr-Abl proteins bind Grb2.
Studies in mouse transplant models established that the Y177F mutant of Bcr-Abl is deficient in inducing myeloid leukemia, confirming the important role of tyrosine 177 in generating the oncogenic phenotype produced by the Bcr-Abl oncoprotein (Zhang et al., 2001; He et al., 2002) .
Tyrosine phosphorylation reduces the serine/threonine kinase activity of the Bcr protein Studies were done to search for other possible effects of tyrosine phosphorylation of Bcr in first exon sequences. Surprisingly, tyrosine phosphorylation of the Bcr protein by the Bcr-Abl protein strongly reduced its serine/threonine kinase activity (Liu et al., 1996b) . Since Y283, Y328 and Y360 were also phosphorylated by the Abl kinase domain within the Bcr-Abl oncoprotein, experiments were performed to determine whether any of these tyrosine residues were involved in inhibiting the Bcr serine/threonine kinase. Mutation of Y360 to phenylalanine (F) strongly inhibited the ability of the Bcr protein (P160 BCR) to phosphorylate an added substrate in kinase reactions. Similarly, the Y328F mutant also curtailed Bcr transkinase activity, but this mutation also reduced the ability of Bcr to autophosphorylate on serine residues. The double mutant Y328F/Y360F blocked both the trans-and autokinase activities of the Bcr protein (Wu et al., 1998) . A model was proposed indicating that the hydroxyl groups of tyrosine 328 and 360 are critically involved in regulating Bcr's serine/threonine kinase activity ( Figure 1) (Arlinghaus, 1998) . In this model, phosphorylation of these tyrosyl hydroxyl groups within Bcr would compromise its kinase function (e.g. proper conformation of the kinase domain). Furthermore, it is proposed that the phosphorylation of Y328 and Y360 modifies two cysteine pairs (e.g. oxidation to form S-S bonded pairs), because of the proposed role of the two cysteine pairs in Bcr kinase activity . A similar role for tyrosines residues has been indicated by those working on pyruvate kinase, another novel kinase that requires cysteine residues and tyrosine for its kinase activity (Annamalai and Colman, 1981; Tomich et al., 1981) . Removal of the hydroxyl groups of Y328 and Y360 by mutation of the tyrosine to phenylalanine should have the same result as the phosphorylation of these hydroxyl groups. Since reduction of the Bcr serine/threonine kinase resulted from tyrosine phosphorylation by the activated Abl tyrosine kinase within the Bcr-Abl oncoprotein, then Bcr's serine kinase must have an important role with regards to Bcr-Abl and that its oncogenic activity might require some level of Bcr serine kinase inhibition. By chance it was discovered that removal of the oligomerization domain in a truncated form of Bcr (Bcr(64-413)) rendered it resistant to tyrosine phosphorylation by the activated Abl kinase (Liu et al., 1996a) . Later it was found that although the oligomerization domain is required for the maximum level of Bcr serine kinase activity, Bcr(64-413) maintained a significant level of in vitro kinase activity (Hawk et al., 2002) . Co-expression of Bcr(64-413) with over-expressed c-Abl revealed a modest reduction of tyrosine phosphorylation of cAbl as compared to that observed with co-expression with Bcr(1-413); the latter being an excellent target for c-Abl and thus would have reduced serine/threonine kinase activity. Bcr(64-413) also strongly inhibited the Bcr-Abl kinase autophosphorylation activity as judged by kinase assays whereas the heat-denatured Bcr(64-413) protein lost the inhibitory activity (Liu et al., 1996a) . Also, co-expression of c-Abl with Bcr(64-413) formed complexes involving these proteins, and these complexes contained an inactive c-Abl tyrosine kinase. The biological activity of Bcr-Abl was also reduced by co-expression of Bcr(64-413), as expression of Bcr(64-413) in K562 cells reduced its ability to form colonies in soft agar when compared to vector only transfected cells (Liu et al., 1996a) . This paper, also demonstrated that a phosphoserine 354 Bcr peptide but not the nonphosphorylated peptide strongly inhibited the Bcr-Abl tyrosine kinase autophosphorylation reaction. The importance of phosphoserine 354 was confirmed in later studies (Hawk et al., 2002) reviewed below.
Bcr(64-413) expression in CML cell lines and primary cultures inhibits their growth and survival
Because of the inhibitory effects of Bcr(64-413) on colony formation of the CML cell line K562 (Liu et al., 1996a) , this form of Bcr was introduced into other CML cell lines and primary cultures of blood cells of CML patients with active disease by adenovirus infection (Wang et al., 2001) . These studies were performed by using a replication-defective adenovirus encoding either BCR(64-413) or the b galactosidase (GAL) gene. Unfortunately, CML cell lines in log phase growth were resistant to adenovirus b GAL infection; but serum-starved and crowded cells were readily susceptible to adenovirus infection, as 70 -80% of the cells exhibited expression of the b GAL gene following infection with adenovirus b GAL (Wang et al., 2001) . Under these conditions, K562 cells (myeloid blast cells expressing P210 BCR-ABL), BV173 cells (lymphoid blast cells expressing P210 BCR-ABL), primary blood cell cultures from CML patients with active disease, SMS-SB (a pre-B cell lacking BCR-ABL expression), and normal marrow cells had similar levels of infection with the b GAL adenovirus. Infection of these cell lines with adenovirus encoding BCR(64-413) inhibited cell growth of K562 cells but not that of SMS-SB cells. In addition, Bcr(64-413) expression induced high levels of apoptosis in primary CML cells but not normal marrow cells, as measured by annexin V/propidium iodide staining (Wang et al., 2001) . Thus, these findings indicate that Bcr(64-413) antagonizes the oncogenic effects of Bcr-Abl but had no detectable toxic effects on hematopoietic cells lacking Bcr-Abl expression at least in short-term tissue culture experiments. These findings also raise the possibility of utilizing some form of Bcr to treat CML.
Induction of BCR gene expression in Rat-1 cells transformed by Bcr-Abl reversed the oncogenic phenotype and sharply reduced tyrosine phosphorylation of cellular proteins
Since Bcr(64-413) was inhibitory to the Bcr-Abl tyrosine kinase and blocked its oncogenic effects, studies were performed to test whether full length Bcr would have similar effects. Because Bcr is a target for tyrosine phosphorylation , it was a concern that it may not be able to antagonize the effects of Bcr-Abl. That is, tyrosine phosphorylation of Bcr would inhibit the Bcr serine kinase activity and thus neutralize Bcr's inhibitory effects directed towards Bcr-Abl. Repeated attempts were made to over-express Bcr in Rat-1 cells transformed by Bcr-Abl expression (P185 BCR-ABL), but to our surprise during the selection process Rat-1 cells lacking expression of BcrAbl were selected out, as judged by phosphotyrosine Western blotting. These results suggest that the BcrAbl positive cells were counter-selected as a result of BCR over-expression during the two to three week neomycin (neo) selection period. These findings suggest that excess BCR gene expression antagonizes the oncogenic effects of Bcr-Abl, and thereby induces cell death. Because of these findings, several induceable vector systems were tested to introduce a transcriptionally silent form of the BCR cDNA into Bcr-Abl cells, which would permit induction of BCR gene expression to determine the initial effects of Bcr on the Bcr-Abl oncogenic phenotype. The tetracycline (Tet) repression system was chosen (Wu et al., 1999) . In order to maximize the induction of the Bcr protein and to insure a low level of synthesis of exogenous Bcr in the non-induced condition, various clones of transfected Bcr-Abl expressing cells were selected in soft agar (as a means to select oncogenic Rat-1 cell clones) under neo selection conditions. It was found that the larger the size of the cell colony, the lower the level of leaky Bcr expression in the presence of Tet. Induction of exogenous Bcr expression inhibited foci formation of Bcr-Abl transformed Rat-1 cells and reduced the phosphotyrosine content of cellular proteins (Wu et al., 1999) . However, the effects of BCR expression on a CML cell line (K562 cells) were considerably less drastic in culture than that observed in Bcr-Abl positive fibroblastic cells. Induction of BCR expression in K562 cells caused an increase in cell differentiation. Further studies are under way on the characteristics of CML cell lines like K562 following induction of the Bcr protein. (Y Wang and R Arlinghaus, unpublished) .
Despite these less drastic effects in a CML cell such as K562, the phosphotyrosine/phosphoserine content of the Bcr protein were examined following BCR induction. Before induction, the endogenous Bcr protein had a high level of phosphotyrosine compared to phosphoserine. After BCR induction, the level of Bcr protein increased several fold within 5 -15 days. After increasing the Bcr concentration, the percentage of phosphotyrosine Bcr within the pool of total Bcr decreased dramatically whereas the content of phosphoserine Bcr increased to the point that Bcr was predominantly in the phosphoserine form . This was of interest to us, since Rat-1 fibroblastic cells transformed by Bcr-Abl were greatly inhibited by this phosphoserine form of Bcr but K562 cells, when maintained in tissue culture, were somehow able to survive these inhibitory effects in cell culture.
Bcr expression blocks leukemia formation in a NOD/scid mouse model
Despite the more subtle effects of enhanced BCR expression on CML cell line clones containing a Tetrepressed BCR cDNA maintained in culture compared to Rat-1 cells transformed by Bcr-Abl, we tested the effects of induced BCR expression on CML cell line clones following their injection into NOD/scid mice . In a series of three experiments with a clone (K6) of K562 cells (selected for low BCR expression by colony formation in soft agar), the dose of CML cells necessary for adequate engraftment was tested based on Southern blotting to detect human DNA. Under optimum conditions when BCR induction is prevented by feeding mice tetracycline (Tet) in the drinking water, 100% of mice died within 35 days. Release of the block in BCR expression at the time of intravenous injection, allowed 80% of the mice to survive for a 55 day period. The remaining 20% of mice died of the same leukemia syndrome (an extramedullary disease). These results were reproduced in two additional experiments with this K6 cell clone.
BCR induction after the leukemia process was under way, delayed the onset of death in most animals and allowed longer-term survival in 30% of the animals with what appeared to be a chronic leukemia syndrome. Of interest, one of three mice had no detectable hematopoietic tumors or any other types of tumors.
The leukemia syndrome was interesting in that the mice died of either a wasting syndrome with no detectable tumors in spleens, marrow and liver or died of neoplasia of these tissues either combined with or without a wasting syndrome . Pathology studies revealed that mice with the wasting syndrome had either atrophy of cellular hematopoiesis in spleen/marrow or tumors or both. In another clone of K562 cells (K7), also selected for low expression of the Bcr protein under control of the Tet promoter, the wasting syndrome was also observed (but at a lower frequency, about 40%) in NOD/scid mice in which BCR expression was blocked but death occurred at later times than the K6 clone. Also in K7 injected mice, solid tumors were detected at non-hematopoietic sites when BCR expression was repressed (Y Wang, T Sun and R Arlinghaus, unpublished). Induction of BCR expression reduced these leukemia effects in a dosedependent manner.
These findings prompted us to propose a model that describes the relationship of Bcr protein levels in leukemic cells to the degree of aggressiveness of the disease in CML patients (Wu et al., 1999; Lin et al., 2001) (Figure 2 ). CML patients are typically diagnosed with a benign phase of the leukemia, which if untreated progresses to a more aggressive state (e.g. blast crisis). In this model, the ratio of Bcr protein to the Bcr-Abl oncoprotein is proposed to be a major factor that determines the aggressiveness of the leukemia. Thus, as predicted by this model, patients with lower Bcr/Bcr-Abl ratios would either progress to more aggressive disease (e.g. from benign phase to accelerated phase and/or blast crisis) in a shorter time frame than higher ratio patients, or be more resistant to therapy (e.g. interferon) than higher ratio patients or both.
Serine 354 of Bcr plays a critical role in the inhibitory effects of Bcr
Earlier studies indicated that a Bcr peptide containing phosphoserine 354 (350-SSRVpSPSPTTYRMFRDK-366) inhibits the tyrosine kinase activity of Bcr-Abl and c-Abl as judged by kinase assays (Liu et al., 1996a) . The non-phosphoserine form of this peptide was inactive as an inhibitor. Moreover, the phosphoserine peptide did not inhibit the c-Src tyrosine kinase. These results were confirmed with a variety of phosphoserine Bcr peptides of varying lengths surrounding serine 354; mutant peptides conserving the phosphoserine-like structure (e.g. S354E) were also inhibitory but the S354A mutant Bcr peptide was not kinase inhibitory (Jiaxin Liu and R Arlinghaus, in preparation).
Using the adenovirus gene delivery system described above, the effects of the S354A mutant of Bcr(64-413) were tested on K562, BV173, and SMS-SB cells (Hawk et al., 2002) . The Bcr(64-413) had the expected result on Bcr-Abl expressing cells, causing growth inhibition and cell death. In contrast, the S354A mutant Bcr(64-413) had little effect on these Bcr-Abl positive cells; the effects of the S354A mutant were similar in magnitude to infection with the b GAL adenovirus (Figure 3) .
Further studies are underway to explore the mechanism by which Bcr(64-413) blocks the effects of the Bcr-Abl oncoprotein. Pendergast et al. (1991) showed that the serine-rich sequences of Bcr bind firmly to the SH2 domain of c-Abl. Surprisingly, this binding was not dependent on the presence of phosphotyrosine sequences. This binding was confined to two serine-rich boxes, termed A and B boxes encoded within the first exon of the BCR gene; the most efficient binding was observed from the B box domain that includes Bcr serine 354. Our findings indicate that phosphoserine forms of Bcr are important for Bcr's inhibitory effects (Hawk et al., 2002; Liu et al., 1996a) . Phosphoserine Bcr(64-413) as measured by Western blotting with a sequence specific phosphoserine 354 antibody bound tightly to the Abl SH2 domain in binding experiments conducted with GST-Abl SH2 (Figures 4 and 5) (Hawk et al., 2002) . Surprisingly, the S354A mutant of Bcr(64-413) had no detectable Abl SH2 binding ability (Figure 4) . Thus, the ability of Bcr(64-413) to bind to the Abl SH2 domain correlated with its ability to inhibit Bcr-Abl's oncogenic activity.
Also current studies are examining the nature of the Bcr(64-413) binding to the Abl SH2 domain. Our findings at this point indicate that a unique structural form of Bcr binds to the Abl SH2 domain (Hawk et al., 2002) . It was noticed that slower migrating forms of Bcr, either full length or deletion mutant forms containing the coiled-coil domain (McWhirter et al., 1993) , are present in denaturing SDS polyacrylamide gels. These altered form of full length Bcr were more reproduceably extracted from COS1 cells in an extraction buffer containing a non-ionic detergent buffer (Abe et al., 2001) . In contrast, Bcr(64-413) usually required initial extraction in a buffer containing a non-ionic detergent and sodium desoxycholate, termed Guo buffer (Hawk et al., 2002) . Under these conditions, it was observed that Bcr(64-413) exists in two forms, a 45 -47 kDa and a 55 kDa form ( Figure  4 ). Both forms are recognized by antibodies made against Bcr peptides 181 -194 and 298 -310. Importantly both forms are recognized by a sequence-specific phosphoserine 354 antibody . Importantly, the S354A mutant generated only the 45 -47 kDa form and not the 55 kDa form. Moreover, the phosphoserine-containing 55 kDa form but not the 45 -47 kDa form was able to bind tightly to the Abl SH2 domain (Figures 4 and 5) . Therefore, the lack of The 55 kDa form of Bcr(64-413) binds to GST-Abl SH2. In these experiments BCR(64-413) transfected COS1 cells were lysed and incubated with GST or GST-Abl SH2 and Western blotted with anti-Bcr(298-310) as described (Hawk et al., 2002) . Lane 1, the total lysate of COS1 cells expressing Bcr(64-413) S354A; lane 2, the total lysate COS1 cells expressing Bcr(64-413); lane 3, lysate of Bcr(64-413) S354A incubated on ice with 50 mg of GST beads and the bound portion was eluted with boiling SDS sample buffer; lane 4, lysate of Bcr(64-413) S354A incubated with 50 mg of GST-Abl SH2 beads and the bound portion was eluted with boiling SDS sample buffer; lane 5, lysate of Bcr(64-413) incubated with 50 mg of GST beads and the bound portion was eluted with boiling SDS sample buffer; lane 6, lysate of Bcr(64-413) incubated with 50 mg of GST-Abl SH2 beads, eluted as above. The lane marked M is the molecular weight marker. The top of the lanes are marked with either Mu to identify the mutant Bcr(64-413) S354A or Wt to identify wild-type Bcr(64-413) Abl SH2 binding by the S354A mutant of Bcr(64-413) and its inability to form the unique 55 kDa form of Bcr(64-413) strongly suggest that a unique form of phosphoserine Bcr is required for binding to the Abl SH2 domain. Importantly, the inability of the S354A Bcr mutant to block Bcr-Abl's oncogenic effects, suggests that the formation of the unique form of Bcr appears to be a critical step in Bcr's inhibitory properties directed towards the Bcr-Abl oncoprotein.
The SH2 domain is well known to bind to phosphotyrosine-containing peptide sequences, with each SH2 domain having a different consensus phosphotyrosine peptide sequence. The FLVRES sequence is highly conserved among SH2 domains and mutation of this sequence interferes with its phosphotyrosine binding ability (Mayer et al., 1992) . Experiments were conducted to compare Bcr(1-413) binding to both wild-type and a FLVRES mutant Abl SH2 (R to L within the FLVRES sequence). No difference in Bcr(1-413) binding to either wild-type or mutant SH2 domain was observed (Hawk et al., 2002) . These findings indicate that it is the phosphoserine form of Bcr that binds to the Abl SH2 domain, but it does not appear to bind to the site within the Abl SH2 domain that binds phosphotyrosine peptide sequences. Moreover, the role of serine 354 of Bcr in this binding is critical, since the S354A mutant of Bcr(64-413) does not bind to the Abl SH2 domain, nor does the S354A mutant produce the slower migrating form, which is the form of Bcr(64-413) that binds to the SH2 domain.
As discussed above, serine 354 of Bcr is a crucial amino acid required for inhibition of the Bcr-Abl kinase and for formation of the slower migrating form of Bcr(64-413) (Hawk et al., 2002) . The slower migrating form of Bcr(64-413) with a mobility of about 55 kDa is likely to be a hyperphosphorylated form of the 45 kDa form of , and that serine 354 plays a gatekeeper role, because the S354A mutant is unable to form the slower migrating form of . One possible interpretation is that phosphorylation of serine 354 is required for additional serine and or /threonine residues to be phosphorylated. The kinase responsible for phosphorylation of serine 354 is likely to include Bcr itself. Kinase assays and peptide mapping experiments performed with Bcr(1-413) wild-type and the S354A mutant proteins obtained from BCR transfected cells detected the loss of a single phosphotryptic peptide spot from the mutant Bcr protein, as determined by 2-D mapping experiments (N Hawk, Ph.D. thesis). Bcr is also phosphorylated at serine 354 in transfected COS1 cells, as determined by Western blotting with a sequencespecific phosphoserine 354 antibody . These results indicate serine 354 is a site of phosphorylation within Bcr, and possibly a site of Bcr autophosphorylation. However, the possibility that a serine kinase other than Bcr can also phosphorylate serine 354 can not be eliminated at this time.
Currently other sites of serine phosphorylation within Bcr are being explored. Serine 356 of Bcr has been identified as a site of phosphorylation, using phosphoserine sequence-specific antibodies prepared from phosphoserine Bcr peptides . Of interest, the sequence in this region of Bcr is 346-SSGQSSRVSPSPTTYR.; the bolded serine-prolineserine-proline sequence includes serines 354 and 356. Further studies are underway to provide information about the unique structural forms of Bcr and how they allow firm binding to the Abl SH2 domain. Importantly, it is suggested that the Abl SH2 binding of phosphoserine Bcr perturbs the structure of the SH2 domain, thereby interfering with the kinase activity of the Abl tyrosine kinase.
Model for Bcr inhibition of Bcr-Abl
Figure 6 depicts a model that fits our findings obtained thus far. Briefly, the phosphorylation of Bcr on serine residues including serine 354 creates a precursor structure, which upon further serine (or threonine) phosphorylation leads to a unique structural form of Bcr (pSerBcr**). The presence of serine 354 is required for the formation of the unique structural species that binds to the Abl SH2 domain. This form of Bcr is associated with structures in the cell that make it difficult to solubilize with negatively charged strong detergents like sodium dodecyl sulfate (SDS). Also, this form of Bcr is resistant to tyrosine phosphorylation by Bcr-Abl, as shown in studies with Tet-off clones of K562 cells that over-express Bcr upon removal of the Tet block (Wu et al., 1999; Lin et al., 2001) . This resistance to tyrosine phosphorylation is believed to result from either its unique phosphoserine structure (e.g it is phosphorylated on either several or many serine residues and therefore adopts a conformation that is resistant to Abl kinase phosphorylation) or from its ability to bind to and perturb the SH2 domain of Bcr-Abl, or both. The binding of phosphoserine Bcr to the SH2 domain apparently does not involve the same SH2 sequence necessary for phosphotyrosine peptide binding, as mutation of the conserved FLVRES sequence of the SH2 domain (R to L), which interferes with phosphotyrosine peptide binding, had no effect on phosphoserine Bcr binding (Hawk et al., 2002) . This result suggests that the phosophoserine Bcr binding site is different from the pocket in the SH2 domain that binds phosphotyrosine. Thus by some new mechanism, the unique phosphoserine structure of Bcr binds firmly to a different site within the Abl SH2 domain than the phosphotyrosine pocket.
Although the phosphorylation of serine 354 is required for the formation of the unique Bcr structure within Bcr(64-413), our unpublished studies indicate that Bcr proteins that contain the first 63 amino acids may have back-up serine or threonine residues that can serve as gatekeeper residues. The first 63 amino acids contain an oligomerization domain (coiled-coil structure, McWhirter et al., 1993) . Therefore, it is possible that serine 354, which is located in the serine-rich B box of Bcr, may be essential for Bcr(64-413) to form the unique structure, but intact Bcr because of its higher kinase activity due to the tetramer structure might provide one or more back-up serine residues that can partially substitute for serine 354 and therefore allow the structural change to occur but at a lower frequency, when serine 354 is changed to alanine (Jiaxin Liu, Jacki Lin, and R Arlinghaus, unpublished).
The phosphotyrosine-independent binding of proteins to SH2 domains has been reported in two other systems (Cleghon et al., 1994; Park et al., 1995) besides the Bcr/Abl SH2 system (Pendergast et al., 1991; Muller et al., 1992) . One describes the interaction of Raf-1 with the SH2 domains of Fyn and Src (Cleghon et al., 1994) . The other concerns the interaction of a 62,000 molecular weight protein with the SH2 domain of p56 Lck in a phosphotyrosineindependent manner.
These studies raise questions about how the binding of the phosphoserine Bcr structure affects the Abl catalytic domain and the adjacent SH2 domain. A recent study on the c-Abl protein provides evidence that the amino terminal 80 amino acids auto-inhibits the Abl tyrosine kinase activity (Pluk et al., 2002) . A model describing the three-dimensional arrangement of the c-Abl protein and its regulatory motifs was presented. The N-terminal 80 residues is represented as a rod structure that binds to the catalytic domain (SH1) of the Abl protein, thereby stabilizing the downregulated structural form (having reduced kinase activity) in which the SH3 domain is bound to the linker sequence between the SH2 domain and the SH1 domain. The resulting structure is viewed as a 'closed structure' from the point of access to ATP and/or substrate.
In the Bcr-Abl oncoproteins, the amino terminal portion of the c-Abl sequence is of course deleted which would remove the auto-inhibitory block. Moreover, the oligomerization of the Bcr-Abl protein would further facilitate the activation of the Abl tyrosine kinase by cross-phosphorylation of key tyrosines in the Bcr-Abl protein. As shown in Figure 6 , the binding of phosphoserine Bcr to the SH2 domain is viewed as an event that re-establishes the 'closed structure' of the Abl catalytic complex of SH3/SH2/SH1 in a way that although different from that produced by the amino terminal Abl sequence, effectively down-regulates the kinase activity of Abl. Figure 6 Model describing the interaction of phosphoserine Bcr with the SH2 domain of Bcr-Abl. The model illustrates a two-step serine phosphorylation process and subsequent conformational change of Bcr involving serine 354. Following phosphorylation of serine 354, a unique structural form of Bcr is produced by further serine phosphorylation. This form is identified as pSer Bcr**. The pSer Bcr** structure is proposed to bind to a site within the SH2 domain of the Abl sequence causing perturbation of the catalytic domain, which leads to reduced tyrosine kinase activity. In essence the data predict a two site model for the SH2 domain. One site binds phosphotyrosine, and a second site binds phosphoserine Bcr
